| Description |
HBV-IN-20 is a potent and oral active HBV inhibitor with an EC50 of 0.46 µM. HBV-IN-20 is a typical type II CpAM (core protein assembly modulators)[1].
|
| Related Catalog |
|
| Target |
EC50: 0.46 µM (HBV)[1]
|
| In Vitro |
HBV-IN-20 (compound 61) (5 µM; 6 days) is a typical type II CpAM (core protein assembly modula tors)[1]. Western Blot Analysis[1] Cell Line: HepDES19 cells Concentration: 5 µM Incubation Time: Result: Was a typical type II CpAM (core protein assembly modula tors).
|
| In Vivo |
HBV-IN-20 (3 mg/kg for i.v.; 10 mg/kg for p.o.) shows 69% of oral bioavailability[1]. Pharmacokinetic Parameters of HBV-IN-20 in mouse[1]. Compd Admin. Cl-obs (mL/min/kg) T1/2 (hr) AUClast (h*ng/mL) Vss-obs (L/kg) Cmax (ng/mL) F (%) 61 i.v. 25.5 0.6 1952 0.8 p.o. 0.7 4516 2727 69Mouse; 3 mg/kg for i.v.; 10 mg/kg for p.o. Animal Model: Mouse[1] Dosage: Administration: 3 mg/kg for i.v.; 10 mg/kg for p.o. Result: Showed 69% of oral bioavailability.
|
| References |
[1]. Hwang N, et al. 4-Oxooctahydroquinoline-1(2H)-carboxamides as hepatitis B virus (HBV) capsid core protein assembly modulators. Bioorg Med Chem Lett. 2022; 58:128518.
|
